Calcitriol Patent Expiration
Calcitriol was first introduced by Esjay Pharma Llc
Calcitriol Patents
Given below is the list of patents protecting Calcitriol, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Calcijex |
US6051567 (Pediatric) | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
Feb 02, 2020
(Expired) | Abbvie |
| Calcijex |
US6265392 (Pediatric) | Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol |
Feb 02, 2020
(Expired) | Abbvie |
| Calcijex |
US6274169 (Pediatric) | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
Feb 02, 2020
(Expired) | Abbvie |
| Calcijex | US6051567 | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
Aug 02, 2019
(Expired) | Abbvie |
| Calcijex | US6265392 | Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol |
Aug 02, 2019
(Expired) | Abbvie |
| Calcijex | US6274169 | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
Aug 02, 2019
(Expired) | Abbvie |
Calcitriol's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Calcitriol:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| The GranStone Trial | Martin Blomberg Jensen | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2, PHASE3 |
| Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 | Calcilytix Therapeutics, Inc., a BridgeBio company | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| Management of Iron Deficiency Anemia in Hemodialysis Patients | Beni-Suef University | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis | Sanofi | NA |
TERMINATED
(Jun 1, 2026)
| PHASE3 |
| Vitamin D and Breast Cancer: Does Weight Make a Difference? | Melinda Telli | NA |
TERMINATED
(Apr 1, 2026)
| PHASE2 |
| Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia | BPGbio | NA |
COMPLETED
(Apr 1, 2026)
| PHASE1 |